NIPER and Genzyme India sign MoU for biotechnology fellowships

lunchlexicographerBiotechnology

Dec 1, 2012 (4 years and 8 months ago)

389 views

NIPER and Genzyme India sign MoU for biotechnology fellowships
'Genzyme India Fellowships' to promote academic excellence
New Delhi, Delhi, September 30, 2009 /
India PRwire
/
-- Genzyme, one of the world’s foremost biotechnology
companies, today announced a tie-up with NIPER (National Institute of Pharmaceutical Education and Research)
under the Department of Pharmaceuticals, Government of India for two ‘Genzyme India Fellowships’ for
excellence in biotechnology.
Prof. P. Ramarao, Director, NIPER and Mr. Sandeep Sahney, Managing Director, Genzyme India Pvt. Ltd. signed
the MoU in New Delhi in the presence of Sh. Ashok Kumar, IAS, Secretary, Department of Pharmaceuticals,
Ministry of Chemicals & Fertilizers, Government of India.
As per the terms of the MoU, NIPER – a premier pharmaceutical research institute, would be provided grants by
Genzyme India to support its research program. One fellowship of Rs10,000/- per month would be provided for two
years to a post graduate student and a second fellowship of Rs 16,000/- per month for three years to a Ph.D.
candidate.
“We are very pleased to collaborate with Genzyme India” said Prof. P Ramarao, Director, NIPER. “This
partnership will contribute significantly in the newly emerging area of biotechnology research,” he added.
Based on the demands of the Indian Pharmaceutical industry and the unique requirements of the pharmaceutical
industry in the global economic scenario, the Government of India notified the establishment of the Department of
Pharmaceuticals under the aegis of the Ministry of Chemicals and Fertilizers in July, 2008. This collaboration gels
well with the Department’s Vision 2020 for strengthening country’s biotechnology capacity to positively impact the
lives of Indian people.
On the occasion of the MoU signing, Sandeep Sahney, Managing Director, Genzyme India and South Asia said,
“This MoU with NIPER is one more way of demonstrating Genzyme’s commitment to India, and follows the earlier
collaboration with ICGEB in November last year. We are confident the ‘Genzyme India Fellowships’ will act as a
catalyst in promoting academic excellence and applied research.”
Notes to Editor
About NIPER:
National Institute of Pharmaceutical Education and Research (NIPER) is the first national level institute in
pharmaceutical sciences with the proclaimed objective of becoming a centre of excellence for advanced studies
and research in pharmaceutical sciences. The Government of India has declared NIPER as an ‘Institute of
National Importance’. NIPER is an autonomous body set up under the aegis of the Department of
Pharmaceuticals, Ministry of Chemicals and Fertilizers, Government of India. The Institute has been conceived to
provide leadership in pharmaceutical sciences and related areas not only within India, but also to countries in
South-east Asia, South Asia and Africa. NIPER is a member of Association of Indian Universities and Association
of Commonwealth Universities.
About Genzyme:
One of the world’s leading biotechnology companies, Genzyme is dedicated to making a major positive impact on
the lives of people with serious diseases. Since 1981, the company has grown from a small start-up to a diversified
enterprise with more than 11,000 employees in locations spanning the globe and 2008 revenues of $4.6 billion.
With many established products and services helping patients in nearly 100 countries, Genzyme is a leader in
developing and applying the most advanced technologies in the life sciences. The Company’s products and
services are focused on rare inherited disorders, kidney disease, orthopaedics, cancer, transplant and immune
diseases and diagnostic testing. Genzyme’s commitment to innovation continues today with a substantial
page 1 / 2
development program focused on these fields, as well as cardiovascular disease, neurodegenerative diseases and
other areas of unmet medical needs.
In its first two years of existence, Genzyme India has introduced four novel treatments, besides strengthening
compassionate access for another four therapies targeted at genetic disorders. Genzyme India is engaged in
clinical development and has also entered into collaboration with ICGEB (International Centre for Genetic
Engineering & Biotechnology) in the area of Malaria research.
© copyright 2012
India PRwire
(http://www.indiaprwire.com)
India PRwire disclaims any content contained in press release. Use of our service is governed by our privacy policy and terms of service.
page 2 / 2